EBS Emergent Biosolutions Inc.

103.33
-1.01  -1%
Previous Close 104.34
Open 104.11
52 Week Low 46.37
52 Week High 137.61
Market Cap $5,468,728,780
Shares 52,924,889
Float 37,920,376
Enterprise Value $6,003,535,495
Volume 419,205
Av. Daily Volume 970,612
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Covid-19 vaccine
COVID-19 Vaccine
Phase 1
Phase 1
Phase 1 enrollment to commence September 2020.
CHIKV-VLP
Chikungunya virus
Phase 2
Phase 2
Phase 3 trial to be initiated in 2021.
COVID-EIG
COVID-19
Phase 2
Phase 2
Phase 2 trial to commence 3Q 2020.
COVID-HIG
COVID-19
Phase 2
Phase 2
Phase 2 trial to commence 3Q 2020.
FLU-IGIV
Influenza A
Phase 2
Phase 2
Phase 3 trial to commence in 2020.
VLA1601
Zika vaccine
Phase 1
Phase 1
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
BioThrax
Anthrax Vaccine Adsorbed
Approved
Approved
Approved November 24, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Approved
Approved
Approved March 25, 2015.
BioThrax
Anthrax Vaccine
Approved
Approved
Approved May 17, 2012.

Latest News

  1. DUBLIN, Sept. 2, 2020 /PRNewswire/ -- The "Viral Vector Manufacturing Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

    Research and Markets Logo

    The global viral vector manufacturing market is projected to grow at a CAGR of 22.09% to reach a market size of US$1,469.144 million in 2025 from US$443.592 million in 2019.

    The viral vector market is primarily being driven by the growing adoption of adenoviral vectors, lentiviral vectors, as well as retroviral vectors. The growing adoption stems from the need for effectively transferring therapeutic gene into the target cells that are an integral part of the process that involves the insertion of a functional copy of a gene into a defective cell one of the preferred treatment…

    DUBLIN, Sept. 2, 2020 /PRNewswire/ -- The "Viral Vector Manufacturing Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

    Research and Markets Logo

    The global viral vector manufacturing market is projected to grow at a CAGR of 22.09% to reach a market size of US$1,469.144 million in 2025 from US$443.592 million in 2019.



    The viral vector market is primarily being driven by the growing adoption of adenoviral vectors, lentiviral vectors, as well as retroviral vectors. The growing adoption stems from the need for effectively transferring therapeutic gene into the target cells that are an integral part of the process that involves the insertion of a functional copy of a gene into a defective cell one of the preferred treatment options for most chronic diseases, which is known as Gene therapy.



    Furthermore, the growing number of clinical trials, the increasing number of gene therapy, and the expanding cognizance of effective mode of disease treatment are further expected to drive the growth of the viral vector manufacturing market during the forecast period. Since vector designing, production, packaging, and release testing is subject to limited availability and faced with challenges due to the complex nature of technologies and platform and thus many players in this space often endeavor in striking strategic collaboration and acquisitions that cover many aspects like the delivery of clinical grade product under its ambit, to facilitate the successful collaboration development of viral agent-based products.



    Moreover, the efficient ability to express the therapeutic genes and non-pathogenic nature is another factor that is responsible for driving the growth of this market. The other key factors that are expected to drive the growth of the market are the increasing investment in the biopharmaceutical production coupled with the growing aging population, healthcare expenditure, technological advancement, especially in the genetic engineering segment.



    Moreover, the increasing accessibility of healthcare facilities, the growing demand for treatment of disease due to the increasing global burden of diseases are a few of the other factors that are poised to drive the growth of this market during the forecast period. Nevertheless, despite the transitioning of this niche industry to high manufacturing is one such factor that may restrain the growth of the market to a certain extent.



    Therefore, with such growing recognition of the importance of viral vectors, various developments are taking place in the viral vector manufacturing market. For instance, in June 2020, it was announced by Emergent BioSolutions Inc. (NYSE:EBS) which is a global life sciences company that it is going to invest $75 Million in Canton Site and expand viral vector and gene therapy capability facilitating the reinforcement of its contract development and manufacturing (CDMO) capabilities.



    Again, in June 2020, Oxford Biomedica (LSE: OXB) which is a major gene and cell therapy group, announced that it has signed an agreement of collaboration with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization that has been established to provide the first strategic vaccine development and progressive manufacturing capability in the UK. Under this 5-year agreement, the organization will work towards enabling the manufacture of vaccines that are based on viral vector, to contribute towards a swift growth in the domestic capacity for this specialized field of vaccine manufacturing.



    In April 2020, Merck KGaA (FWB: MRK) a leading science and technology company announced that a 100 million facility, second in Carlsbad, California USA that is intended to boost its BioReliance viral and gene therapy service offering to help their customers to aid their customers to commercialize the gene therapies that are brought about by viral vectors concomitantly helping innovators scale up their production that is in tandem with the quantum that allows them to reach out to more patients.



    Earlier, in January 2020, the launch of ZYNTEGLO (autologous CD34+ cells encoding A-T87Q-globin gene) in Germany was announced by bluebird bio, Inc. (NASDAQ:BLUE). ZYNTEGLO is a one-time gene therapy that has been specifically developed for patients aged 12 years and older with transfusion-dependent -thalassemia (TDT) who do not possess 0/0 genotype.



    In December 2019, it was announced that a leading supplier of services and technologies for the life sciences industry called Novasep launched oXYgene which is a fully integrated offering for the construction of facilities dedicated towards customers to aid them in their viral vector production.



    In October 2019, it was reported that GE Healthcare Life Sciences which has now rebranded itself as Cytiva, was about to launch the KUBio box which is an adaptable, flexible and fully integrated environment for biomanufacturing to accelerate the production gene therapies based on of viral vector. These latest additions were intended to bring gene therapies swiftly to the market thereby contributing to the increased capacity in the viral vector area.



    In March 2018, it was reported that Sartorius Stedim Biotech SA (SSB), which is a major international technology partner supplier of products and services biopharmaceutical industry has been selected by ABL Europe as its chief supplier of single-use systems whereby the new viral vector manufacturing capacity has been started in Strasbourg at its European facility. ABL Europe, a subsidiary of ABL Inc. provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch.



    Key Topics Covered



    1. Introduction

    1.1. Market Definition

    1.2. Market Segmentation



    2. Research Methodology

    2.1. Research Data

    2.2. Assumptions



    3. Executive Summary

    3.1. Research Highlights



    4. Market Dynamics

    4.1. Market Drivers

    4.2. Market Restraints

    4.3. Porters Five Forces Analysis

    4.4. Industry Value Chain Analysis



    5. Viral Vector Manufacturing Market Analysis, By Type

    5.1. Introduction

    5.2. Retroviral vectors

    5.3. Lentiviral Vectors

    5.4. Adenoviral Vectors

    5.5. Others



    6. Viral Vector Manufacturing Market Analysis, By Application

    6.1. Introduction

    6.2. Vaccinology

    6.3. Gene Therapy



    7. Viral Vector Manufacturing Market Analysis, By End-User

    7.1. Introduction

    7.2. Pharmaceutical & Biotechnology Companies

    7.3. Research Institutes

    7.4. Contract Research Organizations



    8. Viral Vector Manufacturing Market Analysis, by Geography

    8.1. Introduction

    8.2. North America

    8.3. South America

    8.4. Europe

    8.5. The Middle East & Africa

    8.6. Asia-Pacific



    9. Competitive Environment and Analysis

    9.1. Major Players and Strategy Analysis

    9.2. Emerging Players and Market Lucrativeness

    9.3. Mergers, Acquisitions, Agreements, and Collaborations

    9.4. Vendor Competitiveness Matrix



    10. Company Profiles

    10.1. Sirion-Biotech GmbH

    10.2. Vigene Biosciences

    10.3. Batavia Biosciences B.V.

    10.4. Virovek

    10.5. Lonza

    10.6. Vector Biolabs

    10.7. Cobra Biologics

    10.8. MaxCyte, Inc.

    10.9. Genelux

    10.10. BioNTech SE



    For more information about this report visit https://www.researchandmarkets.com/r/dozt6p

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    Media Contact:

    Research and Markets

    Laura Wood, Senior Manager





    For E.S.T Office Hours Call +1-917-300-0470

    For U.S./CAN Toll Free Call +1-800-526-8630

    For GMT Office Hours Call +353-1-416-8900



    U.S. Fax: 646-607-1907

    Fax (outside U.S.): +353-1-481-1716





    Cision View original content:http://www.prnewswire.com/news-releases/global-viral-vector-manufacturing-market-2020-2025-growing-adoption-of-adenoviral-vectors-lentiviral-vectors-as-well-as-retroviral-vectors-301122912.html

    SOURCE Research and Markets

    View Full Article Hide Full Article
  2. Dublin, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

    The global viral vector manufacturing market is projected to grow at a CAGR of 22.09% to reach a market size of US$1,469.144 million in 2025 from US$443.592 million in 2019.

    The viral vector market is primarily being driven by the growing adoption of adenoviral vectors, lentiviral vectors, as well as retroviral vectors. The growing adoption stems from the need for effectively transferring therapeutic gene into the target cells that are an integral part of the process that involves the insertion of a functional copy of a gene into a defective cell one of the preferred treatment…

    Dublin, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.



    The global viral vector manufacturing market is projected to grow at a CAGR of 22.09% to reach a market size of US$1,469.144 million in 2025 from US$443.592 million in 2019.



    The viral vector market is primarily being driven by the growing adoption of adenoviral vectors, lentiviral vectors, as well as retroviral vectors. The growing adoption stems from the need for effectively transferring therapeutic gene into the target cells that are an integral part of the process that involves the insertion of a functional copy of a gene into a defective cell one of the preferred treatment options for most chronic diseases, which is known as Gene therapy.



    Furthermore, the growing number of clinical trials, the increasing number of gene therapy, and the expanding cognizance of effective mode of disease treatment are further expected to drive the growth of the viral vector manufacturing market during the forecast period. Since vector designing, production, packaging, and release testing is subject to limited availability and faced with challenges due to the complex nature of technologies and platform and thus many players in this space often endeavor in striking strategic collaboration and acquisitions that cover many aspects like the delivery of clinical grade product under its ambit, to facilitate the successful collaboration development of viral agent-based products.



    Moreover, the efficient ability to express the therapeutic genes and non-pathogenic nature is another factor that is responsible for driving the growth of this market. The other key factors that are expected to drive the growth of the market are the increasing investment in the biopharmaceutical production coupled with the growing aging population, healthcare expenditure, technological advancement, especially in the genetic engineering segment.



    Moreover, the increasing accessibility of healthcare facilities, the growing demand for treatment of disease due to the increasing global burden of diseases are a few of the other factors that are poised to drive the growth of this market during the forecast period. Nevertheless, despite the transitioning of this niche industry to high manufacturing is one such factor that may restrain the growth of the market to a certain extent.



    Therefore, with such growing recognition of the importance of viral vectors, various developments are taking place in the viral vector manufacturing market. For instance, in June 2020, it was announced by Emergent BioSolutions Inc. (NYSE:EBS) which is a global life sciences company that it is going to invest $75 Million in Canton Site and expand viral vector and gene therapy capability facilitating the reinforcement of its contract development and manufacturing (CDMO) capabilities.



    Again, in June 2020, Oxford Biomedica (LSE: OXB) which is a major gene and cell therapy group, announced that it has signed an agreement of collaboration with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization that has been established to provide the first strategic vaccine development and progressive manufacturing capability in the UK. Under this 5-year agreement, the organization will work towards enabling the manufacture of vaccines that are based on viral vector, to contribute towards a swift growth in the domestic capacity for this specialized field of vaccine manufacturing.



    In April 2020, Merck KGaA (FWB: MRK) a leading science and technology company announced that a 100 million facility, second in Carlsbad, California USA that is intended to boost its BioReliance viral and gene therapy service offering to help their customers to aid their customers to commercialize the gene therapies that are brought about by viral vectors concomitantly helping innovators scale up their production that is in tandem with the quantum that allows them to reach out to more patients.



    Earlier, in January 2020, the launch of ZYNTEGLO (autologous CD34+ cells encoding A-T87Q-globin gene) in Germany was announced by bluebird bio, Inc. (NASDAQ:BLUE). ZYNTEGLO is a one-time gene therapy that has been specifically developed for patients aged 12 years and older with transfusion-dependent -thalassemia (TDT) who do not possess 0/0 genotype.



    In December 2019, it was announced that a leading supplier of services and technologies for the life sciences industry called Novasep launched oXYgene which is a fully integrated offering for the construction of facilities dedicated towards customers to aid them in their viral vector production.



    In October 2019, it was reported that GE Healthcare Life Sciences which has now rebranded itself as Cytiva, was about to launch the KUBio box which is an adaptable, flexible and fully integrated environment for biomanufacturing to accelerate the production gene therapies based on of viral vector. These latest additions were intended to bring gene therapies swiftly to the market thereby contributing to the increased capacity in the viral vector area.



    In March 2018, it was reported that Sartorius Stedim Biotech SA (SSB), which is a major international technology partner supplier of products and services biopharmaceutical industry has been selected by ABL Europe as its chief supplier of single-use systems whereby the new viral vector manufacturing capacity has been started in Strasbourg at its European facility. ABL Europe, a subsidiary of ABL Inc. provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch.



    Key Topics Covered



    1. Introduction

    1.1. Market Definition

    1.2. Market Segmentation



    2. Research Methodology

    2.1. Research Data

    2.2. Assumptions



    3. Executive Summary

    3.1. Research Highlights



    4. Market Dynamics

    4.1. Market Drivers

    4.2. Market Restraints

    4.3. Porters Five Forces Analysis

    4.4. Industry Value Chain Analysis



    5. Viral Vector Manufacturing Market Analysis, By Type

    5.1. Introduction

    5.2. Retroviral vectors

    5.3. Lentiviral Vectors

    5.4. Adenoviral Vectors

    5.5. Others



    6. Viral Vector Manufacturing Market Analysis, By Application

    6.1. Introduction

    6.2. Vaccinology

    6.3. Gene Therapy



    7. Viral Vector Manufacturing Market Analysis, By End-user

    7.1. Introduction

    7.2. Pharmaceutical & Biotechnology Companies

    7.3. Research Institutes

    7.4. Contract Research Organizations



    8. Viral Vector Manufacturing Market Analysis, by Geography

    8.1. Introduction

    8.2. North America

    8.3. South America

    8.4. Europe

    8.5. The Middle East & Africa

    8.6. Asia-Pacific



    9. Competitive Environment and Analysis

    9.1. Major Players and Strategy Analysis

    9.2. Emerging Players and Market Lucrativeness

    9.3. Mergers, Acquisitions, Agreements, and Collaborations

    9.4. Vendor Competitiveness Matrix



    10. Company Profiles

    10.1. Sirion-Biotech GmbH

    10.2. Vigene Biosciences

    10.3. Batavia Biosciences B.V.

    10.4. Virovek

    10.5. Lonza

    10.6. Vector Biolabs

    10.7. Cobra Biologics

    10.8. MaxCyte, Inc.

    10.9. Genelux

    10.10. BioNTech SE



    For more information about this report visit https://www.researchandmarkets.com/r/w8y0mk

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT: ResearchAndMarkets.com
             Laura Wood, Senior Press Manager
             
             For E.S.T Office Hours Call 1-917-300-0470
             For U.S./CAN Toll Free Call 1-800-526-8630
             For GMT Office Hours Call +353-1-416-8900
    

    Primary Logo

    View Full Article Hide Full Article
  3. GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of potentially lifesaving overdose reversal medicines on International Overdose Awareness Day 2020. International Overdose Awareness Day is a global event held on August 31 each year that aims to raise awareness of overdose and reduce the stigma of drug-related deaths. Emergent, in collaboration with these teams and MAPDA, will address the importance of accessing overdose reversal medicines through special announcements, videos, and stadium presentations.

    "Emergent is committed…

    GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of potentially lifesaving overdose reversal medicines on International Overdose Awareness Day 2020. International Overdose Awareness Day is a global event held on August 31 each year that aims to raise awareness of overdose and reduce the stigma of drug-related deaths. Emergent, in collaboration with these teams and MAPDA, will address the importance of accessing overdose reversal medicines through special announcements, videos, and stadium presentations.

    "Emergent is committed to doing everything we can to increase awareness, access, and availability of potentially lifesaving overdose reversal medicines," said Doug White, SVP and devices business unit head at Emergent BioSolutions. "We are proud to team up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA on International Overdose Awareness Day to highlight the important role that overdose reversal medicines play in preparing individuals and families in the event of an accidental opioid overdose. Everyone can take a stand and take action by talking to their doctor or pharmacists about having immediate access to overdose reversal medicines."

    "By increasing awareness about the importance of having immediate access to overdose reversal medicines, we may empower individuals to be prepared in the event of an opioid overdose emergency," said Mary Bono, former U.S. Congresswoman and chairman and CEO of MAPDA. "MAPDA is honored to stand alongside Emergent, the Boston Red Sox, Cincinnati Reds, and Philadelphia Phillies, to help more individuals know about and access potentially lifesaving medicines to treat opioid overdoses."

    For more information, visit: www.cutoutoverdoses.com.

    About Emergent BioSolutions

    Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what's most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.

    About MAPDA

    Mothers Against Prescription Drug Abuse (MAPDA) is a nonprofit consumer organization started by three mothers who lost children to prescription drug overdoses. The organization aims to prevent prescription drug abuse before it starts and support individuals in recovery. Mary Bono, a well-known political speaker and consumer advocate, now heads up the organization headquartered in the Washington DC suburbs. Learn more at MAPDA.net.

    Media Contact:

    Miko B. Neri

    Senior Director, Global Communications & Public Affairs

    240-631-3392

     

    Investor Contact:

    Robert G. Burrows

    Vice President, Investor Relations

    240-631-3280

      

    Primary Logo

    View Full Article Hide Full Article
  4. GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the 2023 annual meeting of stockholders. Mr. White was also appointed as a member of both the Scientific Review Committee and Strategic Operations Committee of the board.

    "We welcome Marvin back to Emergent's Board of Directors," said Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions. "He brings invaluable financial and management expertise gained from his time in the pharmaceutical and healthcare sectors. We look forward to his contributions in…

    GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the 2023 annual meeting of stockholders. Mr. White was also appointed as a member of both the Scientific Review Committee and Strategic Operations Committee of the board.

    "We welcome Marvin back to Emergent's Board of Directors," said Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions. "He brings invaluable financial and management expertise gained from his time in the pharmaceutical and healthcare sectors. We look forward to his contributions in advising company leadership on how to further grow and increase shareholder value."

    "I am delighted to serve on the board of a mission-driven organization focused on public health," said Mr. White. "As Emergent executes on its growth strategy, I embrace the opportunity to work with my distinguished colleagues on the board as well as the management team to help move the company forward."   

    Mr. White has served as president and chief executive officer and member of the board of directors of Aptevo Therapeutics Inc. since August 2016. He previously served on Emergent's board from 2010 to 2016. Prior to that, he served as chief financial officer of St. Vincent Health and was responsible for finance, patient financial services, and managed care for 19 hospitals and 36 joint ventures. Previously, he was chief financial officer of Lilly USA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking. 

    Prior to his career in healthcare, Mr. White held leadership positions at General Motors, Hewlett-Packard, and Motorola, including financial roles for its Japan, South Asia and Latin America Cellular Group. He currently serves on the board of OneAmerica Financial Insurance Partners, Inc. Mr. White earned his Bachelor of Science degree in Accounting from Wilberforce University and his Master of Business Administration in Finance from Indiana University.

    About Emergent BioSolutions

    Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what's most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

    Safe Harbor Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, but no limited to, statements regarding executing on our growth strategy and increasing shareholder value, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements. Investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.

    Investor Contact:

    Robert G. Burrows

    Vice President, Investor Relations

    240-631-3280

     

    Media Contact:

    Miko B. Neri

    Senior Director, Global Communications & Public Affairs

    240-631-3392

    Primary Logo

    View Full Article Hide Full Article
  5. GAITHERSBURG, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's executive management team will participate in the following virtual investor conferences through the end of September 2020:

    • 2020 NYSE Healthcare & Technology Investor Access Day
      August 18 – virtual one-on-one meetings only
       
    • 2020 Three Part Advisors Virtual Midwest IDEAS Investor Conference
      August 27 – pre-recorded presentation available beginning at 8:00am eastern
       
    • 2020 Wells Fargo Virtual Healthcare Conference
      September 9 – presentation at 8:00am eastern

    • Robert W. Baird 2020 Global Healthcare Conference
      September 10 – presentation at 2:35pm eastern

    • Morgan Stanley 18th Annual Global Healthcare Conference 2020

    GAITHERSBURG, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's executive management team will participate in the following virtual investor conferences through the end of September 2020:

    • 2020 NYSE Healthcare & Technology Investor Access Day

      August 18 – virtual one-on-one meetings only

       
    • 2020 Three Part Advisors Virtual Midwest IDEAS Investor Conference

      August 27 – pre-recorded presentation available beginning at 8:00am eastern

       
    • 2020 Wells Fargo Virtual Healthcare Conference

      September 9 – presentation at 8:00am eastern



    • Robert W. Baird 2020 Global Healthcare Conference

      September 10 – presentation at 2:35pm eastern



    • Morgan Stanley 18th Annual Global Healthcare Conference 2020

      September 14 – presentation at 4:30pm eastern



    • Cantor Virtual Global Healthcare Conference 2020

      September 15 – presentation at 3:20pm eastern



    • 2020 Singular Research Compelling Values Webcall

      September 17 – presentation at 12:00pm eastern

    For conferences where a presentation is planned, the company's webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the Emergent website www.emergentbiosolutions.com under "Investors."

    About Emergent BioSolutions

    Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what's most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

    Investor Contact:

    Robert G. Burrows

    Vice President, Investor Relations

    240-631-3280

     

    Media Contact:

    Miko B. Neri

    Senior Director, Global Communications & Public Affairs

    240-631-3392

    Primary Logo

    View Full Article Hide Full Article
View All Emergent Biosolutions Inc. News